Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACCELIO
NCT06102057Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Completion Rate at 22 weeks. Started Jul 2024; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06102057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102057.